{"id":60892,"date":"2026-03-24T13:20:03","date_gmt":"2026-03-24T05:20:03","guid":{"rendered":"https:\/\/flcube.com\/?p=60892"},"modified":"2026-03-24T13:20:04","modified_gmt":"2026-03-24T05:20:04","slug":"bio-thera-expands-intas-partnership-to-india-bat2506-golimumab-biosimilar-now-licensed-across-us-canada-and-india","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60892","title":{"rendered":"Bio\u2011Thera Expands Intas Partnership to India \u2013 BAT2506 Golimumab Biosimilar Now Licensed Across US, Canada, and India"},"content":{"rendered":"\n

Bio\u2011Thera Solutions Inc.<\/strong> (SHA: 688177<\/a>) has expanded its strategic partnership<\/strong> with Intas Pharmaceuticals Ltd.<\/strong>, granting the Indian firm exclusive commercialization rights<\/strong> to BAT2506<\/strong>, a biosimilar of Johnson & Johnson’s Simponi (golimumab)<\/strong>, for the Indian market<\/strong> \u2013 completing a tri\u2011market licensing arrangement<\/strong> that now covers US, Canada, and India<\/strong> for the TNF\u2011\u03b1\u2011targeting autoimmune therapy.<\/p>\n\n\n\n

Partnership Expansion Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Bio\u2011Thera Solutions Inc. (SHA: 688177)<\/td><\/tr>
Licensee<\/strong><\/td>Intas Pharmaceuticals Ltd. (India)<\/td><\/tr>
Product<\/strong><\/td>BAT2506 \u2013 golimumab biosimilar (TNF\u2011\u03b1 inhibitor)<\/td><\/tr>
Reference Product<\/strong><\/td>Simponi\u00ae (golimumab, Johnson & Johnson)<\/td><\/tr>
New Territory<\/strong><\/td>India<\/strong> (exclusive commercialization rights)<\/td><\/tr>
Prior Territories<\/strong><\/td>US + Canada<\/strong> (existing Intas exclusive rights)<\/td><\/tr>
Current Intas Portfolio<\/strong><\/td>US, Canada, India<\/strong> \u2013 exclusive BAT2506 rights<\/td><\/tr>
Bio\u2011Thera Responsibilities<\/strong><\/td>R&D, manufacturing, commercial supply<\/td><\/tr>
Intas Responsibilities<\/strong><\/td>In\u2011market commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

BAT2506 Regulatory & Commercial Status<\/h2>\n\n\n\n
Milestone<\/th>Date<\/th>Significance<\/th><\/tr><\/thead>
European Commission Approval<\/strong><\/td>February 2026<\/strong><\/td>Five indications<\/strong>: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, juvenile idiopathic arthritis<\/td><\/tr>
US\/Canada Rights<\/strong><\/td>Prior to March 2026<\/td>Intas exclusive commercialization<\/td><\/tr>
India Rights<\/strong><\/td>March 2026<\/td>Tri\u2011market exclusivity complete<\/strong>; emerging market expansion<\/td><\/tr>
Manufacturing<\/strong><\/td>Bio\u2011Thera\u2011controlled<\/td>Integrated supply chain for global partners<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Context<\/h2>\n\n\n\n
Dimension<\/th>Bio\u2011Thera Position<\/th>Intas Position<\/th><\/tr><\/thead>
Development Model<\/strong><\/td>R&D + manufacturing<\/strong> asset originator<\/td>Commercialization<\/strong> partner with regional expertise<\/td><\/tr>
Global Expansion<\/strong><\/td>Multi\u2011territory licensing strategy reduces direct sales force investment<\/td>Strengthens Intas autoimmune franchise in key markets<\/td><\/tr>
Manufacturing Advantage<\/strong><\/td>China\u2011based biologics production cost structure<\/td>Reliable supply from validated Bio\u2011Thera facilities<\/td><\/tr>
Market Access<\/strong><\/td>Leverages Intas’s established payer relationships and distribution<\/td>Adds premium biosimilar to Intas’s immunology portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Competitive Dynamics<\/h2>\n\n\n\n